These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39261064)

  • 1. A Case of Patient with Atezolizumab-induced Encephalitis in Hepatocellular Carcinoma.
    Otomo K; Fujita M; Sekine R; Sato H; Abe N; Sugaya T; Watanabe C; Takahata Y; Hayashi M; Abe K; Takahashi A; Ohira H
    Intern Med; 2024 Sep; ():. PubMed ID: 39261064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab- and bevacizumab -induced encephalitis in a patient with advanced hepatocellular carcinoma: a case report and literature review.
    Sagong M; Kim KT; Jang BK
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):397. PubMed ID: 39180675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review.
    Satake T; Maruki Y; Kubo Y; Takahashi M; Ohba A; Nagashio Y; Kondo S; Hijioka S; Morizane C; Ueno H; Okusaka T
    Intern Med; 2022 Sep; 61(17):2619-2623. PubMed ID: 35185051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
    Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
    J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
    Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
    Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab-induced encephalitis with subdural hemorrhage and subarachnoid hemorrhage in a patient with hepatocellular carcinoma.
    Chao KH; Tseng TC
    J Formos Med Assoc; 2023 Nov; 122(11):1208-1212. PubMed ID: 37567840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case of Immune-Related Aseptic Meningitis during Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma.
    Kawanaka H; Tajiri K; Muraishi N; Murayama A; Nukui T; Yasuda I
    Case Rep Gastroenterol; 2024; 18(1):8-13. PubMed ID: 38188593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events.
    Hayashi H; Sawada K; Hasebe T; Nakajima S; Sawada J; Takiyama Y; Takiyama Y; Okumura T; Fujiya M
    Intern Med; 2022 Dec; 61(23):3497-3502. PubMed ID: 35491133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.
    Iwasaki S; Hidaka H; Uojima H; Hashimura M; Nabeta T; Sanoyama I; Wada N; Kubota K; Nakazawa T; Shibuya A; Koizumi W
    Clin J Gastroenterol; 2021 Aug; 14(4):1233-1239. PubMed ID: 34024039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma.
    Fukushima M; Tajima K; Sasaki R; Nakao Y; Takahashi K; Ozawa E; Miuma S; Kato T; Miyaaki H; Nakao K
    Clin J Gastroenterol; 2023 Jun; 16(3):402-406. PubMed ID: 36746879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab-associated encephalitis in metastatic breast cancer: A case report.
    Chen G; Zhang C; Lan J; Lou Z; Zhang H; Zhao Y
    Oncol Lett; 2022 Sep; 24(3):324. PubMed ID: 35949609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
    Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of biopsy-proven acute interstitial nephritis following atezolizumab-bevacizumab treatment of advanced unresectable hepatocellular carcinoma.
    Patel R; Elghawy O; Gibbs A; Gupta S; Kaur V
    Cancer Rep (Hoboken); 2024 Jul; 7(7):e2110. PubMed ID: 39051557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
    Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report.
    Bian LF; Zheng C; Shi XL
    World J Clin Cases; 2021 Jun; 9(16):4110-4115. PubMed ID: 34141773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence.
    Hosoda K; Toshima T; Takahashi J; Yonemura Y; Hisamatsu Y; Hirose K; Masuda T; Motomura Y; Abe T; Ando Y; Dairaku K; Nakano Y; Hashimoto M; Hiraki Y; Soejima Y; Yoshizumi T; Mimori K
    Int Cancer Conf J; 2023 Oct; 12(4):274-278. PubMed ID: 37577350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma.
    Baigi T; Brown EN; De La Torre RM; Abu-Shahin FI
    J Oncol Pharm Pract; 2023 Oct; 29(7):1757-1761. PubMed ID: 37282559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.